Mads M. Engelmann
Soborg, 2860, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
Journal: The Journal of clinical endocrinology and metabolism
Published: April 10, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
Journal: JAMA cardiology
Published: March 25, 2026
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
Journal: JAMA internal medicine
Published: February 02, 2026
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
Journal: The lancet. Diabetes & endocrinology
Published: January 21, 2026
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Journal: Circulation
Published: November 10, 2025
Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease.
Journal: Journal of the American College of Cardiology
Published: August 26, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Journal: The New England journal of medicine
Published: March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Journal: Circulation
Published: March 29, 2025
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
Journal: Diabetes, obesity & metabolism
Published: January 13, 2023
Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings.
Journal: Journal of clinical pharmacology
Published: October 06, 2022
Last Updated: 09/26/2026